This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.

This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.

A participant will be placed into one of two groups: Group A: Usual Care vs. Group B: SDM Toolkit according to the randomized placement of the assigned study clinician.

Study procedures include questionnaires and option interviews with study staff.

Participation in this research study is expected to last about 2 years.

It is expected about 52 clinicians and 312 participants will take part in this research study.

The National Institute on Aging is providing funding for this research study

Participant Inclusion Criteria:

• Women aged ≥ 80 years at the time of registration

• History of stage 0-III breast cancer (Of note: ductal carcinoma in situ [DCIS], pleomorphic lobular carcinoma in situ [because it is typically treated like DCIS], or invasive breast cancer of any subtype are all eligible)

• No history of a recurrent breast cancer (i.e., a breast cancer that is deemed metastatic or a locoregional recurrence of a prior cancer per clinician judgement rather than a new primary breast cancer). If a person has been diagnosed with multiple distinct breast cancers over time (e.g., history of left and right breast cancer), they are eligible as long as they meet other requirements for time since surgery, etc.

• Has at least one intact breast

• Has had mammogram screening/surveillance within the last 24 months

  -≥ 12 months since most recent breast surgery to affected breast (e.g., breast reduction surgery on an unaffected breast within 12 months is ok)

• No active cancer-directed therapy other than hormonal therapy and/or CDK 4/6 inhibitor therapy

• Ability and willingness to take surveys

• Receiving at least some of their oncology follow-up care at a participating site

• Most recent mammogram report for the potential participant did not recommend additional diagnostic work-up or close interval follow-up imaging

  • If a patient required diagnostic breast testing in the past or at the time of the most recent mammogram AND the results were resolved to benign findings with no additional diagnostics recommended, they are eligible.
  • If a patient's most recent mammogram result isn't yet available at the time of approach or study consent, the patient is eligible to proceed with consent and enrollment. If this mammogram then abnormal or requires additional imaging, that patient will not be included in the study analyses or surveys. This patient will be replaced.

Participant Exclusion Criteria:

• Inability to provide informed consent
• Assigned male sex at birth
• Breast or recent imaging findings requiring diagnostic testing at baseline
• Prior discontinuation of mammography by electronic medical record (EMR) review or patient report
• Prior atypical ductal hyperplasia (ADH) or non-pleomorphic LCIS only
• Psychiatric illness situations that would limit compliance with study requirements
• Those with metastatic breast cancer
• Those in hospice care
• Those whose clinician is not willing to participate
• Pregnant women, young patients, and those in prison will not be eligible for enrollment given the study design and aims supporting study in a different population focused on older adults

Clinician Inclusion Criteria:

• Must be an active clinician (MD, NP, or PA) at a participating institution
• Sees at least one breast-cancer survivor aged ≥ 80
• Clinician must be able to read, speak, and write in English

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Data can be shared no earlier than 1 year following the date of publication

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

randomized to having educational material or not.